drugset / Trial / NCT03261102
TDM Guided Early Optimization of ADAL in Crohn's Disease
RandomizedParallel-groupTriple-blindTreatment
Summary
To investigate the influence of early therapeutic drug monitoring and dose optimization on disease outcome in Crohn's patients treated with Adalimumab.
Timeline
- Start
- 2017-01-17
- Primary completion
- 2025-01-15
- Completion
- 2025-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Adalimumab | Monoclonal antibody | 40 mg | Subcutaneous |